Technical Articles

The KRAS gene is one of the most frequently mutated oncogenes in human cancers, occurring in approximately 10-25% of non-small cell lung cancer cases and is closely associated with poor prognosis.

The KRAS gene is one of the most commonly mutated oncogenes in lung cancer, discovered over two decades earlier than the EGFR gene. However, compared to the rapid development of EGFR-targeted therapies, targeted treatments for KRAS-mutated non-small cell lung cancer have long lagged behind.

The KRAS gene, as one of the most frequently mutated oncogenes in human cancers, has long been considered an "undruggable" target due to its protein structural characteristics.

The KRAS G12C mutation is one of the key driver gene alterations in non-small cell lung cancer, accounting for approximately 4% of NSCLC patients in Asia. Due to its unique molecular structural characteristics, KRAS G12C has long been considered an "undruggable" target, posing significant challenges in clinical treatment.

The KRAS gene is one of the most frequently mutated driver genes in tumors and plays a critical role in various malignant cancers, including non-small cell lung cancer, colorectal cancer, and pancreatic cancer.

KRAS gene mutation is one of the most common driver gene variations in non-small cell lung cancer (NSCLC), widely involved in the occurrence and development of tumors.

Carcinoembryonic antigen (carcinoembryonic antigen cell adhesion molecule 5, CEA) is a glycosylated cell surface adhesion molecule belonging to the carcinoembryonic antigen cell adhesion molecule family.